• Insight Molecular Diagnostics Inc IMDX.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of four analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -31 cents to -24 cents per share.

• Revenue fell 98.5% to $32.00 thousand from a year ago; analysts expected $300.00 thousand.

• Insight Molecular Diagnostics Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $4.29 million.

• Insight Molecular Diagnostics Inc shares had risen by 51.8% this quarter and lost 33.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 30.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $9.00, about 43.3% above its last closing price of $5.10

This summary was machine generated from LSEG data May 14 at 12:00 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)